Pharmaceuticals
Asieris Pharmaceuticals Unveils 2023 Semi-Annual Report, Demonstrating Initial Success of Specialty Pharma Strategy and Multi-Product Synergistic Commercialization
SHANGHAI, Aug. 22, 2023 /PRNewswire/ -- Asieris Pharmaceuticals (Stock Code: 688176.SH) – a global innovative pharmaceutical company specializing in the discovery, development and commercialization of innovative drugs that treat genitourinary (GU) tumors and other related diseases – today release...
2023-08-22 20:58
2026
Sanyou Biopharmaceuticals and Sinorda Biomedicine signed Strategic Cooperation Agreement for Advancing Innovative Drug Research and Development
SHANGHAI, Aug. 22, 2023 /PRNewswire/ -- Sanyou Biopharmaceuticals (Shanghai) Co., Ltd. (referred to as "Sanyou" hereafter) and Sinorda Biomedicine (referred to as " Sinorda " hereafter) have officially signed a strategic cooperation agreement to advance the innovative bispecific antibody drug pro...
2023-08-22 20:00
1628
CARsgen Announced 2023 Interim Results
SHANGHAI, Aug. 22, 2023 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announced its 2023 Interim Results. Business Highlights * Collaboration agr...
2023-08-22 19:30
3123
Kintor Pharma Announces Completion of Patient Enrollment in Phase II Clinical Trial of GT20029 for Treatment of Androgenetic Alopecia in China
SUZHOU, China, Aug. 22, 2023 /PRNewswire/ -- Kintor Pharmaceutical Limited ("Kintor Pharma", HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, announced that the company has completed the enrollment of 180 patients for the Phase...
2023-08-22 17:13
1120
Introducing NeoMab™: GemPharmatech's Innovative Antibody Gene Humanized Mouse Model
SAN DIEGO, Aug. 21, 2023 /PRNewswire/ -- GemPharmatech is proud to announce the launch of NeoMab™, our independently developed fully antibody gene humanized mouse model, after four years of rigorous research and validation. NeoMab™ is specifically designed to meet the burgeoning therapeutic antib...
2023-08-22 08:59
1286
CanariaBio Achieves Significant Milestone with FDA's Orphan Drug Designation for MAb-AR20.5 Targeting Pancreatic Cancer
The investigational monoclonal antibody becomes the first to target Mucin 1 (MUC1) and receive this designation. PYEONGTAEK, South Korea, Aug. 21, 2023 /PRNewswire/ -- CanariaBio Inc., a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative immun...
2023-08-21 20:00
1628
TradeUP Acquisition Corp. Announces Extension of the Deadline for an Initial Business Combination
NEW YORK, Aug. 18, 2023 /PRNewswire/ -- TradeUP Acquisition Corp. (the "Company" or "TradeUP") (NASDAQ: UPTD) today announced that, in order to extend the date by which the Company must complete its initial business combination fromAugust 19, 2023 to September 19, 2023, for each public share that...
2023-08-19 04:30
5037
Akeso Announced First Patient Dosed in Phase 3 Trial of Ivonescimab versus Tislelizumab for First-line Treatment of Squamous NSCLC
HONG KONG, Aug. 18, 2023 /PRNewswire/ -- Akeso Inc. ("Akeso", 9926. HK) announced today that the first patient has been dosed in a head-to-head phase III trial of ivonescimab, a potential first-in-class investigational PD-1/VEGF bi-specific antibody discovered by Akeso. The Phase III trial will e...
2023-08-18 20:00
5914
Inmagene's anti-OX40 mAb demonstrated an extended half-life and a favorable safety profile in a Phase I study
* IMG-007 has the potential to provide Q12W or less frequent dosing based on an extended half-life * IMG-007 has demonstrated a favorable safety profile, consistent with a silenced ADCC function via bioengineering * IMG-007 is being evaluated in two global proof-of-concept trials SAN DIEGO,...
2023-08-18 19:00
4490
JinMed (NASDAQ: ZJYL) Rings the Nasdaq Stock Market Closing Bell on August 17
CHANGZHOU, China, Aug. 17, 2023 /PRNewswire/ -- Jin Medical International Limited ("the Company" or "JinMed") (NASDAQ: ZJYL), the world's leading provider of rehabilitation equipment, rang the bell at the New York Stock Exchange by its Chairman and CEOWang Erqi on August 17, to celebrate the Com...
2023-08-18 11:36
4003
Thrombotic AEs of Hemlibra (emicizumab) were 2.8 times more frequent than those of FVIII replacements.
* Analyzed the FDA FAERS data…to compare the thrombotic AEs of Hemlibra vs. FVIII replacements. YONGIN, South Korea, Aug. 17, 2023 /PRNewswire/ -- GC Biopharma (006280.KS), a South Korean biopharmaceutical company, announced on August 17, 2023 that it has presented the results of analyzing and...
2023-08-18 08:58
2038
Neurophth Announces First Patient Dosed in Phase I/II Clinical Trial of Second Gene Therapy
WUHAN, China and SAN DIEGO, Aug. 17, 2023 /PRNewswire/ -- Neurophth Therapeutics, Inc. ("Neurophth") announced today that the first patient has been dosed in the international multi-region, multi-center Phase I/II clinical trial for the treatment of Leber hereditary optic neuropathy caused byND1 ...
2023-08-17 21:00
1205
Minghui Pharmaceutical Inc. Announces First Patient Enrollment in the Phase 3 Clinical Study of MH004 Cream for Treatment of Mild to Moderate Atopic Dermatitis
SHANGHAI, HANGZHOU, China and WILMINGTON, Del., Aug. 17, 2023 /PRNewswire/ -- Minghui Pharmaceutical, Inc., a leading clinical-stage biopharmaceutical company, today announced the successful enrollment of the first patient in the phase 3 clinical study for MH004 Cream targeting mild to moderate a...
2023-08-17 19:00
4117
I-Mab Provides Mid-Year 2023 Financial Results, Business and Corporate Updates
* Significant progress made year-to-date on key clinical assets: ‐ Uliledlimab (CD73 antibody): Encouraging early results were presented at ASCO 2023 ‐ Givastomig (Claudin 18.2 x 4-1BB bispecific antibody): Topline Phase 1 data with promising early efficacy signals, including pat...
2023-08-17 18:00
4103
2023WCLC Oral Presentation | Molecular Analysis Validates the Effectiveness of Tumor Tissue-Based and Plasma ctDNA Testing in Identifying NSCLC Patients with EGFR Exon20ins Eligible for Treatment with Sunvozertinib
* A high concordance was observed between tumor tissue-based and plasma circulating tumor DNA (ctDNA) testing in detecting EGFR exon 20 insertion (Exon20ins) mutations. * Both tumor tissue-based and plasma ctDNA testing can be used to identify patients who may benefit from treatment with su...
2023-08-17 17:10
1937
Nippon Express (Ireland) Opens New Warehouse in Dublin, Beginning Operations July 1
TOKYO, Aug. 16, 2023 /PRNewswire/ -- Nippon Express (Ireland) Ltd. (hereafter "NX Ireland"), a group company of NIPPON EXPRESS HOLDINGS, INC., has established a new warehouse, "Contract Logistics Center," inDublin city, beginning its operations onJuly 1. Logo: https://kyodonewsprwire.jp/img/2023...
2023-08-16 14:00
1158
Inmagene's OX40 mAb, with an extended half-life and silenced ADCC, enters POC study in Atopic Dermatitis
SAN DIEGO, SHANGHAI and SYDNEY, Aug. 15, 2023 /PRNewswire/ -- Inmagene Biopharmaceuticals ("Inmagene"), a clinical stage biotechnology company developing innovative and differentiated therapies for immunological and inflammatory diseases, announced that the first patient has been dosed in a glob...
2023-08-15 22:50
1827
OnCusp Therapeutics Receives FDA Clearance for the Phase 1 Clinical Trial of CUSP06, Targeting Ovarian Cancer and Other Advanced Solid Tumors
NEW YORK, Aug. 15, 2023 /PRNewswire/ -- OnCusp Therapeutics, a biopharmaceutical company dedicated to transforming cutting-edge preclinical innovation into clinically validated treatments for cancer patients worldwide, announced today the clearance of its Investigational New Drug (IND) Applicatio...
2023-08-15 20:00
1050
Asieris Announces Positive Phase III Bridging Trial of Hexvix®, a Diagnostic Drug for Bladder Cancer
SHANGHAI, Aug. 11, 2023 /PRNewswire/ -- Asieris Pharmaceuticals (688176), a global biopharma company specializing in discovering, developing and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases, announced that the Phase III bridging clinical tr...
2023-08-11 17:00
3770
WuXi XDC and Boostimmune Sign MOU for Integrated Services
SHANGHAI, Aug. 10, 2023 /PRNewswire/ -- WuXi XDC, a leading global Contract Research, Development and Manufacturing Organization (CRDMO) focused on the ADC and broader bioconjugate market, and Boostimmune, a biotech company dedicated to developing next-generation anti-cancer therapies modulating ...
2023-08-11 08:30
1312
Week's Top Stories
Most Reposted
Earth Day 2024: Angel Yeast Continues to Tackle Plastic Pollution Challenges With Bio-based Material Solutions
[Picked up by 294 media titles]
2024-04-22 16:00
Trina Solar and PetroGreen Partner to Accelerate Philippine Solar Adoption with 117MW Supply Agreement
[Picked up by 291 media titles]
2024-04-22 06:00
China's Yiwu Establishes Welcoming Committee to Attract International Buyers
[Picked up by 286 media titles]
2024-04-19 13:25
Revenue Surpasses 50 Billion: BlueFocus Accelerates Towards the AI Native Era
[Picked up by 275 media titles]
2024-04-23 15:43
INTAMSYS Becomes 3D Printing Equipment Supplier for the WORLDSKILLS LYON 2024 COMPETITION
[Picked up by 271 media titles]
2024-04-24 17:09
Most Read
Combining Sustainability and Cybersecurity: Century Iron & Steel and Century Wind Power Both Receive ISO 27001 Information Security Certification
2024-04-19 18:03
9174
With unique features, Hainan TV opened "The World's Specialty" pavilion at the Expo!
2024-04-18 21:26
8847
Animated Life in Yunnan
2024-04-18 14:00
7831
China's Yiwu Establishes Welcoming Committee to Attract International Buyers
2024-04-19 13:25
7752